抗ro52 /SS-A抗体血清阳性Sjögren综合征患者的临床表现。

IF 2.7 Q3 IMMUNOLOGY
Immunological Medicine Pub Date : 2021-12-01 Epub Date: 2021-05-14 DOI:10.1080/25785826.2021.1919342
Hideki Nakamura, Shimpei Morimoto, Toshimasa Shimizu, Ayuko Takatani, Shin-Ya Nishihata, Atsushi Kawakami
{"title":"抗ro52 /SS-A抗体血清阳性Sjögren综合征患者的临床表现。","authors":"Hideki Nakamura,&nbsp;Shimpei Morimoto,&nbsp;Toshimasa Shimizu,&nbsp;Ayuko Takatani,&nbsp;Shin-Ya Nishihata,&nbsp;Atsushi Kawakami","doi":"10.1080/25785826.2021.1919342","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The relationship between anti-Ro52/SS-A antibody (anti-Ro52) and the clinical manifestations of Sjögren's syndrome (SS) has not been fully clarified. We determined the clinical factors relevant to SS patients with anti-Ro52.<b>Methods:</b> We conducted a retrospective study of 149 subjects suspicious for SS and 50 healthy control subjects. We analyzed items of the American-European Consensus Group (AECG) criteria and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).<b>Results:</b> SS was documented in 115 subjects. Anti-Ro52 was observed in 70 SS patients. Anti-Ro52 positivity showed a significantly higher association with anti-Ro60 positivity than with anti-centromere antibody (ACA) positivity (<i>p</i> < 0.05). Regarding the difference in the anti-Ro52 concentration, we observed six significantly relevant components: two AECG components and four non-AECG components. The anti-Ro52 concentration well-discriminated three clinical factors (ROC AUC >0.75), i.e., ACA seropositivity, ESSDAI score ≥1, and RF, and it moderately discriminated high serum IgG, focus score ≥1, and anti-La/SS-B antibody seropositivity (ROC AUC >0.7). A linear relationship between the ESSDAI score and the anti-Ro52 concentration was observed.<b>Conclusion:</b> A significant association between clinical factors (including the ESSDAI) and the anti-Ro52 concentration were revealed. Anti-Ro52 was more highly associated with anti-Ro60 positivity than with ACA positivity.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":"44 4","pages":"252-262"},"PeriodicalIF":2.7000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/25785826.2021.1919342","citationCount":"5","resultStr":"{\"title\":\"Clinical manifestations in anti-Ro52/SS-A antibody-seropositive patients with Sjögren's syndrome.\",\"authors\":\"Hideki Nakamura,&nbsp;Shimpei Morimoto,&nbsp;Toshimasa Shimizu,&nbsp;Ayuko Takatani,&nbsp;Shin-Ya Nishihata,&nbsp;Atsushi Kawakami\",\"doi\":\"10.1080/25785826.2021.1919342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> The relationship between anti-Ro52/SS-A antibody (anti-Ro52) and the clinical manifestations of Sjögren's syndrome (SS) has not been fully clarified. We determined the clinical factors relevant to SS patients with anti-Ro52.<b>Methods:</b> We conducted a retrospective study of 149 subjects suspicious for SS and 50 healthy control subjects. We analyzed items of the American-European Consensus Group (AECG) criteria and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).<b>Results:</b> SS was documented in 115 subjects. Anti-Ro52 was observed in 70 SS patients. Anti-Ro52 positivity showed a significantly higher association with anti-Ro60 positivity than with anti-centromere antibody (ACA) positivity (<i>p</i> < 0.05). Regarding the difference in the anti-Ro52 concentration, we observed six significantly relevant components: two AECG components and four non-AECG components. The anti-Ro52 concentration well-discriminated three clinical factors (ROC AUC >0.75), i.e., ACA seropositivity, ESSDAI score ≥1, and RF, and it moderately discriminated high serum IgG, focus score ≥1, and anti-La/SS-B antibody seropositivity (ROC AUC >0.7). A linear relationship between the ESSDAI score and the anti-Ro52 concentration was observed.<b>Conclusion:</b> A significant association between clinical factors (including the ESSDAI) and the anti-Ro52 concentration were revealed. Anti-Ro52 was more highly associated with anti-Ro60 positivity than with ACA positivity.</p>\",\"PeriodicalId\":37286,\"journal\":{\"name\":\"Immunological Medicine\",\"volume\":\"44 4\",\"pages\":\"252-262\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/25785826.2021.1919342\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunological Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/25785826.2021.1919342\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/5/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/25785826.2021.1919342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/5/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 5

摘要

背景:抗ro52 /SS- a抗体(anti-Ro52)与Sjögren's综合征(SS)临床表现的关系尚不完全清楚。我们确定了与SS患者抗ro52相关的临床因素。方法:对149例疑似SS患者和50例健康对照进行回顾性研究。我们分析了欧美共识组(AECG)标准和EULAR Sjögren综合征疾病活动指数(ESSDAI)的项目。结果:115名受试者出现SS。70例SS患者检测到抗ro52。抗ro52阳性与抗ro60阳性的相关性显著高于抗着丝粒抗体(ACA)阳性(p < 0.05)。关于抗ro52浓度的差异,我们观察到6个显著相关成分:2个AECG成分和4个非AECG成分。抗ro52浓度较好地区分ACA血清阳性、ESSDAI评分≥1、RF三个临床因素(ROC AUC >0.75),中度区分高血清IgG、focus评分≥1、抗la /SS-B抗体血清阳性(ROC AUC >0.7)。ESSDAI评分与抗ro52浓度呈线性关系。结论:临床因素(包括ESSDAI)与抗ro52浓度有显著相关性。Anti-Ro52阳性与anti-Ro60阳性的相关性高于ACA阳性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical manifestations in anti-Ro52/SS-A antibody-seropositive patients with Sjögren's syndrome.

Background: The relationship between anti-Ro52/SS-A antibody (anti-Ro52) and the clinical manifestations of Sjögren's syndrome (SS) has not been fully clarified. We determined the clinical factors relevant to SS patients with anti-Ro52.Methods: We conducted a retrospective study of 149 subjects suspicious for SS and 50 healthy control subjects. We analyzed items of the American-European Consensus Group (AECG) criteria and the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI).Results: SS was documented in 115 subjects. Anti-Ro52 was observed in 70 SS patients. Anti-Ro52 positivity showed a significantly higher association with anti-Ro60 positivity than with anti-centromere antibody (ACA) positivity (p < 0.05). Regarding the difference in the anti-Ro52 concentration, we observed six significantly relevant components: two AECG components and four non-AECG components. The anti-Ro52 concentration well-discriminated three clinical factors (ROC AUC >0.75), i.e., ACA seropositivity, ESSDAI score ≥1, and RF, and it moderately discriminated high serum IgG, focus score ≥1, and anti-La/SS-B antibody seropositivity (ROC AUC >0.7). A linear relationship between the ESSDAI score and the anti-Ro52 concentration was observed.Conclusion: A significant association between clinical factors (including the ESSDAI) and the anti-Ro52 concentration were revealed. Anti-Ro52 was more highly associated with anti-Ro60 positivity than with ACA positivity.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Immunological Medicine
Immunological Medicine Medicine-Immunology and Allergy
CiteScore
7.10
自引率
2.30%
发文量
19
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信